LOGIN
Dabigatran: potential higher risk of acute coronary event compared to other anticoagulants
September 2013
Dabigatran: potential higher risk of acute coronary event compared to other anticoagulants
Study Type:Meta-analysis/Systematic Review
OE Level Evidence:2
Journal Level of Evidence:N/A
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials
Arch Intern Med. 2012 Mar 12;172(5):397-402. doi: 10.1001/archinternmed.2011.1666. Epub 2012 Jan 9Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
In this meta-analysis, 7 studies (30,514 participants with atrial fibrillation (AF)) reporting the risk of developing myocardial infarction (MI) or acute coronary syndrome (ACS) from the use of dabigatran etexilate were evaluated. In comparison to warfarin, enoxaparin, or placebo, results indicated that dabigatran was associated with an increased risk of myocardial infarction (MI) and acute corona...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.